The global medulloblastoma drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of medulloblastoma and the introduction of new drugs in the market. Dianhydrogalactitol, IM5471, Ipilimumab, Indoximod are some of the types that are used for treatment in this disease. Hospital and clinic are two major applications for these drugs. North America is expected to be one of the leading markets for these drugs due to its high incidence rate and increasing awareness about cancer treatments among people living there.
Some Of The Growth Factors Of This Market:
- The incidence of medulloblastoma is increasing in children and adolescents, which is driving the growth of the market.
- The number of new cases diagnosed each year has increased by about 2% annually since 1975, with an estimated 1,500 new cases diagnosed in the US in 2016.
- Medulloblastoma is a type of cancer that starts in the brain and spinal cord tissue called "medulla oblongata.".
- Medulloblastomas are most common among children aged 5-9 years old and adolescents aged 10-19 years old.
- There are no known risk factors for medulloblastoma.
Industry Growth Insights published a new data on “Medulloblastoma Drug Market”. The research report is titled “Medulloblastoma Drug Market research by Types (Dianhydrogalactitol, IMP-5471, Ipilimumab, Indoximod, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Bayer AG, Bristol-Myers Squibb Company, DelMar Pharmaceuticals Inc, Ignyta Inc, IMPACT Therapeutics Inc, Lipocure Ltd, MacroGenics Inc, NewLink Genetics Corp, Novogen Ltd, Ono Pharmaceutical Co Ltd, Progenics Pharmaceuticals Inc, Stemline Therapeutics Inc, ThromboGenics NV, VBI Vaccines Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Medulloblastoma Drug Market Research Report
By Type
Dianhydrogalactitol, IMP-5471, Ipilimumab, Indoximod, Others
By Application
Hospital, Clinic, Others
By Companies
Bayer AG, Bristol-Myers Squibb Company, DelMar Pharmaceuticals Inc, Ignyta Inc, IMPACT Therapeutics Inc, Lipocure Ltd, MacroGenics Inc, NewLink Genetics Corp, Novogen Ltd, Ono Pharmaceutical Co Ltd, Progenics Pharmaceuticals Inc, Stemline Therapeutics Inc, ThromboGenics NV, VBI Vaccines Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Medulloblastoma Drug Market Report Segments:
The global Medulloblastoma Drug market is segmented on the basis of:
Types
Dianhydrogalactitol, IMP-5471, Ipilimumab, Indoximod, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- Bristol-Myers Squibb Company
- DelMar Pharmaceuticals Inc
- Ignyta Inc
- IMPACT Therapeutics Inc
- Lipocure Ltd
- MacroGenics Inc
- NewLink Genetics Corp
- Novogen Ltd
- Ono Pharmaceutical Co Ltd
- Progenics Pharmaceuticals Inc
- Stemline Therapeutics Inc
- ThromboGenics NV
- VBI Vaccines Inc
Highlights of The Medulloblastoma Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dianhydrogalactitol
- IMP-5471
- Ipilimumab
- Indoximod
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Medulloblastoma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Medulloblastoma drug is a medication that is used to treat medulloblastoma.
Some of the major companies in the medulloblastoma drug market are Bayer AG, Bristol-Myers Squibb Company, DelMar Pharmaceuticals Inc, Ignyta Inc, IMPACT Therapeutics Inc, Lipocure Ltd, MacroGenics Inc, NewLink Genetics Corp, Novogen Ltd, Ono Pharmaceutical Co Ltd, Progenics Pharmaceuticals Inc, Stemline Therapeutics Inc, ThromboGenics NV, VBI Vaccines Inc.
The medulloblastoma drug market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Medulloblastoma Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Medulloblastoma Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Medulloblastoma Drug Market - Supply Chain
4.5. Global Medulloblastoma Drug Market Forecast
4.5.1. Medulloblastoma Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Medulloblastoma Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Medulloblastoma Drug Market Absolute $ Opportunity
5. Global Medulloblastoma Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Medulloblastoma Drug Market Size and Volume Forecast by Type
5.3.1. Dianhydrogalactitol
5.3.2. IMP-5471
5.3.3. Ipilimumab
5.3.4. Indoximod
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Medulloblastoma Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Medulloblastoma Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Medulloblastoma Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Medulloblastoma Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Medulloblastoma Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Medulloblastoma Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Medulloblastoma Drug Demand Share Forecast, 2019-2026
9. North America Medulloblastoma Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Medulloblastoma Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Medulloblastoma Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Medulloblastoma Drug Market Size and Volume Forecast by Type
9.7.1. Dianhydrogalactitol
9.7.2. IMP-5471
9.7.3. Ipilimumab
9.7.4. Indoximod
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Medulloblastoma Drug Demand Share Forecast, 2019-2026
10. Latin America Medulloblastoma Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Medulloblastoma Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Medulloblastoma Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Medulloblastoma Drug Market Size and Volume Forecast by Type
10.7.1. Dianhydrogalactitol
10.7.2. IMP-5471
10.7.3. Ipilimumab
10.7.4. Indoximod
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Medulloblastoma Drug Demand Share Forecast, 2019-2026
11. Europe Medulloblastoma Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Medulloblastoma Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Medulloblastoma Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Medulloblastoma Drug Market Size and Volume Forecast by Type
11.7.1. Dianhydrogalactitol
11.7.2. IMP-5471
11.7.3. Ipilimumab
11.7.4. Indoximod
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Maket Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Medulloblastoma Drug Demand Share, 2019-2026
12. Asia Pacific Medulloblastoma Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Medulloblastoma Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Medulloblastoma Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Medulloblastoma Drug Market Size and Volume Forecast by Type
12.7.1. Dianhydrogalactitol
12.7.2. IMP-5471
12.7.3. Ipilimumab
12.7.4. Indoximod
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Medulloblastoma Drug Demand Share, 2019-2026
13. Middle East & Africa Medulloblastoma Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Medulloblastoma Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Medulloblastoma Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Medulloblastoma Drug Market Size and Volume Forecast by Type
13.7.1. Dianhydrogalactitol
13.7.2. IMP-5471
13.7.3. Ipilimumab
13.7.4. Indoximod
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Medulloblastoma Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Medulloblastoma Drug Market: Market Share Analysis
14.2. Medulloblastoma Drug Distributors and Customers
14.3. Medulloblastoma Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. DelMar Pharmaceuticals Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Ignyta Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. IMPACT Therapeutics Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Lipocure Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. MacroGenics Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. NewLink Genetics Corp
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novogen Ltd
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Ono Pharmaceutical Co Ltd
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Progenics Pharmaceuticals Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Stemline Therapeutics Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. ThromboGenics NV
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. VBI Vaccines Inc
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook